Skip to main content

Table 2 Best CNS response in the cEFR population

From: Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

CNS response

Groups

40 mg orally

once daily

(n = 1)

80 mg orally

once daily

(n = 34)

160 mg orally

once daily

(n = 13)

240 mg orally

once daily

(n = 4)

CR, n (%)

0

1 (3)

1 (8)

0

PR, n (%)

0

21 (62)

10 (77)

1 (25)

SD, n (%)

0

11 (32)

2 (15)

3 (75)

PD, n (%)

1 (100)

0

0

0

NE, n (%)

0

1 (3)

0

0

CNS-ORR (95%CI)

0

65% (47–80%)

85% (55–98%)

25% (1–81%)

CNS-DCR (95%CI)

0

97% (85–100%)

100%

100%

  1. CNS central nervous system, cEFR CNS evaluable-for-response set, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, ORR objective response rate, CI confidence interval, DCR disease control rate